The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
For approximately three decades, autologous hematopoietic cell transplantation (auto-HCT) has been the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after frontline therapy. This approach is limited due to the intensity of chemotherapy and the pro...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-12-01
|
| Series: | Therapeutic Advances in Hematology |
| Online Access: | https://doi.org/10.1177/20406207221141511 |
| _version_ | 1811179212505088000 |
|---|---|
| author | Omar Albanyan Julio Chavez Javier Munoz |
| author_facet | Omar Albanyan Julio Chavez Javier Munoz |
| author_sort | Omar Albanyan |
| collection | DOAJ |
| description | For approximately three decades, autologous hematopoietic cell transplantation (auto-HCT) has been the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after frontline therapy. This approach is limited due to the intensity of chemotherapy and the proportion of patients who relapse after auto-HCT. Since the approval of anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy and novel agents, the treatment paradigm for DLBCL has changed remarkably. Anti-CD19 CAR-T therapy was first approved for relapsed DLBCL after two or more previous lines of therapy with long-lasting responses, with over 50% of patients still alive at 5-year follow-up. Here, we discuss recent randomized phase 3 clinical trials using axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel in the second-line therapy setting compared with the standard of care in transplant-eligible patients who have DLBCL R/R within 12 months of completing chemo-immunotherapy, potentially changing the treatment algorithm for DLBCL. |
| first_indexed | 2024-04-11T06:31:04Z |
| format | Article |
| id | doaj.art-d0f37e1c589a45beb0d82dbb7aa57788 |
| institution | Directory Open Access Journal |
| issn | 2040-6215 |
| language | English |
| last_indexed | 2024-04-11T06:31:04Z |
| publishDate | 2022-12-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Hematology |
| spelling | doaj.art-d0f37e1c589a45beb0d82dbb7aa577882022-12-22T04:40:03ZengSAGE PublishingTherapeutic Advances in Hematology2040-62152022-12-011310.1177/20406207221141511The role of CAR-T cell therapy as second line in diffuse large B-cell lymphomaOmar AlbanyanJulio ChavezJavier MunozFor approximately three decades, autologous hematopoietic cell transplantation (auto-HCT) has been the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after frontline therapy. This approach is limited due to the intensity of chemotherapy and the proportion of patients who relapse after auto-HCT. Since the approval of anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy and novel agents, the treatment paradigm for DLBCL has changed remarkably. Anti-CD19 CAR-T therapy was first approved for relapsed DLBCL after two or more previous lines of therapy with long-lasting responses, with over 50% of patients still alive at 5-year follow-up. Here, we discuss recent randomized phase 3 clinical trials using axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel in the second-line therapy setting compared with the standard of care in transplant-eligible patients who have DLBCL R/R within 12 months of completing chemo-immunotherapy, potentially changing the treatment algorithm for DLBCL.https://doi.org/10.1177/20406207221141511 |
| spellingShingle | Omar Albanyan Julio Chavez Javier Munoz The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma Therapeutic Advances in Hematology |
| title | The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma |
| title_full | The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma |
| title_fullStr | The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma |
| title_full_unstemmed | The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma |
| title_short | The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma |
| title_sort | role of car t cell therapy as second line in diffuse large b cell lymphoma |
| url | https://doi.org/10.1177/20406207221141511 |
| work_keys_str_mv | AT omaralbanyan theroleofcartcelltherapyassecondlineindiffuselargebcelllymphoma AT juliochavez theroleofcartcelltherapyassecondlineindiffuselargebcelllymphoma AT javiermunoz theroleofcartcelltherapyassecondlineindiffuselargebcelllymphoma AT omaralbanyan roleofcartcelltherapyassecondlineindiffuselargebcelllymphoma AT juliochavez roleofcartcelltherapyassecondlineindiffuselargebcelllymphoma AT javiermunoz roleofcartcelltherapyassecondlineindiffuselargebcelllymphoma |